Loading paragraph...
Today's Biggest Stock Losers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| IBG | Innovation Beverage Group | $3.36 | -$2.18 | -39.33% | 1.3M | $3.8M | $3.13$49.25 |
| HSPTU | Horizon Space Acquisition II Corp. | $7.24 | -$4.37 | -37.64% | 232 | $105M | $7.24$13.50 |
| BNAI | Brand Engagement Network | $41.62 | -$14.65 | -26.04% | 66.6K | $328M | $1.18$86.28 |
| OLMA | Olema Pharmaceuticals | $16.28 | -$5.27 | -24.45% | 12.8M | $1.7B | $2.86$36.26 |
| RVPH | Reviva Pharmaceuticals | $2.90 | -$0.68 | -18.95% | 448.5K | $411M | $2.90$24.50 |
| ENGN | enGene | $7.07 | -$1.61 | -18.55% | 102.5K | $581M | $2.65$12.25 |
| RCAX | Tidal Trust II - Defiance Daily Target 2x Long Rcat ETF | $18.34 | -$3.91 | -17.57% | 487.9K | - | $11.66$31.62 |
| EMAT | Evolution Metals & Technologies | $8.15 | -$1.61 | -16.50% | 13K | $28M | $5.50$24.37 |
| RBNE | Robin Energy | $2.18 | -$0.41 | -15.73% | 1.7M | $7.3M | $2.11$102.85 |
| ORIC | ORIC Pharmaceuticals | $11.60 | -$2.11 | -15.39% | 140.4K | $1.4B | $3.90$14.93 |
| MEI | Methode Electronics | $5.68 | -$0.98 | -14.71% | 38.6K | $236M | $5.08$10.78 |
| VCIG | Vci Global | $3.31 | -$0.55 | -14.16% | 299.1K | $4.2M | $3.22$34,646.40 |
| OWLT | Owlet | $6.29 | -$0.97 | -13.36% | 52.2K | $200M | $2.75$16.94 |
| FGI | Fgi Industries | $3.49 | -$0.53 | -13.18% | 35.6K | $7.7M | $2.28$12.62 |
| XBP | Xbp Global | $5.47 | -$0.65 | -10.63% | 31.8K | $72M | $4.11$25.60 |
| SDA | SunCar Technology Group | $2.07 | -$0.23 | -10.00% | 26.9K | $235M | $1.54$5.09 |
| UPC | Universe Pharmaceuticals Inc | $2.65 | -$0.07 | -2.57% | 36K | $1.5M | $2.00$11.00 |
| BGMSP | Bio Green Med Solution | $3.15 | $0.13 | 4.30% | 0.8 | - | $2.95$14.00 |
Related Articles
Featured Article
1 Beaten-Up SPAC Stock to Buy Now
Travis Hoium|Sep 27, 2021
Owlet has had a rough path to public markets, but that's a buying opportunity for investors.
Will Last Week's Biotech IPO Outperform in a Recession?
David Haen|Apr 28, 2020
This cancer drug developer will have smooth sailing ahead -- at least until it reports clinical trial results next year.
